347 related articles for article (PubMed ID: 17713050)
1. [Glucagon-like peptide 1 (GLP-1)].
Parhofer KG
MMW Fortschr Med; 2007 Jun; 149(25-26):41-3. PubMed ID: 17713050
[TBL] [Abstract][Full Text] [Related]
2. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
5. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
7. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results.
Madsbad S
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):463-77. PubMed ID: 19748064
[TBL] [Abstract][Full Text] [Related]
8. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
9. [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
Kern W
MMW Fortschr Med; 2010 Jan; 151 Suppl 4():173-8. PubMed ID: 21595145
[No Abstract] [Full Text] [Related]
10. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
11. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
Reuter H; Erdmann E
Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
[TBL] [Abstract][Full Text] [Related]
12. [Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes].
Scheen AJ
Rev Med Liege; 2007 Apr; 62(4):217-21. PubMed ID: 17566392
[TBL] [Abstract][Full Text] [Related]
13. [New concepts in the treatment of type 2 diabetes].
Meier JJ; Schmidt WE; Klein HH
Internist (Berl); 2007 Jul; 48(7):698, 700-7. PubMed ID: 17541529
[TBL] [Abstract][Full Text] [Related]
14. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
Camafort-Babkowski M
Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
[TBL] [Abstract][Full Text] [Related]
15. [Exenatid and its position as antidiabetic drug in the treatment of type 2 diabetes mellitus].
Perusicová J
Vnitr Lek; 2008 Apr; 54(4):377-86. PubMed ID: 18630617
[TBL] [Abstract][Full Text] [Related]
16. Emerging GLP-1 receptor agonists.
Lund A; Knop FK; Vilsbøll T
Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?].
Lüdemann J
MMW Fortschr Med; 2011 Jul; 153 Suppl 2():56-63. PubMed ID: 23964469
[TBL] [Abstract][Full Text] [Related]
18. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
Garber AJ
Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S279-84. PubMed ID: 21525469
[No Abstract] [Full Text] [Related]
19. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
Gallwitz B
Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291
[TBL] [Abstract][Full Text] [Related]
20. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.
González C; Beruto V; Keller G; Santoro S; Di Girolamo G
Expert Opin Investig Drugs; 2006 Aug; 15(8):887-95. PubMed ID: 16859392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]